Cost-effectiveness of digital therapeutics for essential hypertension

Akihiro Nomura, MD, PhD[1-2*], Tomoyuki Tanigawa, MD, MPH[3],

Kazuomi Kario, MD, PhD[4], Ataru Igarashi, PhD[5-6*]

[1] Innovative Clinical Research Center, Kanazawa University, Kanazawa, Japan

[2] Department of Biomedical Informatics, CureApp Institute, Karuizawa, Japan

[3] CureApp, Inc., Tokyo, Japan

[4] Division of Cardiovascular Medicine, Department of Medicine, School of Medicine, Jichi Medical University, Tochigi, Japan

[5] Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Yokohama, Japan

[6] Health Economics & Outcomes Research, Graduate School of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

* These authors contributed equally.

Corresponding author:

Ataru Igarashi, PhD

Associate Professor

Unit of Public health and Preventive Medicine

Yokohama City University School of Medicine, Yokohama, Japan

E-mail: atarui1@mac.com

Abstract

Background: Hypertension increases the risk of cardiovascular and other diseases. Lifestyle

modification is a significant component of nonpharmacological treatments for hypertension.

We previously reported the clinical efficacy of digital therapeutics (DTx) in the HERB-DH1

trial. However, there is still a lack of cost-effectiveness assessments evaluating the impact of

prescription DTx. This study aimed to analyze the cost-effectiveness of using prescription DTx

in treating hypertension.

Methods: We developed a monthly cycle Markov model and conducted Monte Carlo

simulations using the HERB-DH1 trial data to investigate quality-adjusted life-years (QALYs)

and the cost of DTx for hypertension plus guideline-based lifestyle modification consultation

treatment as usual (TAU), comparing DTx+TAU and TAU-only groups with a lifetime horizon.

The model inputs were obtained from the HERB-DH1 trial, published or publicly available

data, and expert assumptions. The incremental cost-effectiveness ratio (ICER) per QALY was

used as the benchmark for cost-effectiveness. We performed probabilistic sensitivity analyses

(PSAs) using the Monte Carlo simulation with 2 million sets.

Results: The DTx+TAU strategy produced 18.778 QALY and was associated with ¥3,924,075

($34,122) expected costs, compared with 18.686 QALY and ¥3,813,358 ($33,160) generated

by the TAU-only strategy over a lifetime horizon, resulting in an ICER of ¥1,199,880

($10,434)/QALY gained for DTx+TAU. The monthly cost and attrition rate of DTx for

hypertension have a significant impact on ICERs. In the PSA, the probability of the DTx arm

being a cost-effective option was 87.8% at a threshold value of ¥5 million ($43,478)/QALY

gained.

Conclusions: The DTx+TAU strategy was more cost-effective than the TAU-only strategy.

Introduction

Hypertension or elevated blood pressure (BP) is a serious health condition that significantly increases cardiovascular diseases (CVD), heart failure (HF), atrial fibrillation (AFib), renal dysfunction, and other disorders.[1] Hypertension affects 1.28 billion people and is a leading modifiable risk factor attributing mortality worldwide.[1, 2] In Japan, there were more than 43 million patients with hypertension, having one of the highest prevalence among the Organization for Economic Co-operation and Development countries.[3] Hypertension is attributed to cerebral and cardiovascular deaths, accounting for 50% of all CVD deaths, 59% of coronary artery disease (CAD) deaths, and 52% of stroke deaths.[4] Also, the total medical cost of these CVDs has reached nearly $100 billion in Japan.[5] Therefore, managing hypertension is one of the most critical issues for preventing CVDs and reducing medical costs in Japan. For this purpose, Health Japan 21 (the second edition) aims to reduce the average systolic BP (SBP) of the Japanese population by 4 mmHg within 10 years by raising awareness and promoting lifestyle modification by a healthy diet, more physical activity, and reducing alcohol consumption at the national level.[6]

Lifestyle modification is a major component of non-pharmacological treatment for hypertension, which is as essential as antihypertensive pharmacological treatment.[7] In principle, hypertensive patients at low risk for CVD should modify their lifestyle first, and antihypertensive drug therapy is initiated at an appropriate time according to the patients' future CVD risks. Lifestyle modification plays a vital role in lowering blood pressure because of its antihypertensive and synergistic effects along with antihypertensive drugs.[8, 9] However, the physician's limited outpatient time is insufficient to provide guideline-based hypertension management, including lifestyle modification suited for each patient's diverse lifestyle.[10] As a result, lifestyle modification has not achieved its full effect in reducing BP.

To maximize the potential treatment effect of lifestyle modification for hypertension,

we developed a prescription digital therapeutics (DTx) for hypertension, the HERB system.[11]

The HERB system consists of a HERB Mobile smartphone app for patients and a web-based

patient management software for primary doctors.[11] We previously reported the HERB-DH1

phase III randomized controlled trial (RCT) results of the DTx for essential hypertension. In

this trial, we randomly assigned 390 essential hypertension patients aged ≤65 years who were

not taking antihypertensive medication to the DTx intervention group or the control group. The

results showed that the primary outcome of the 24-h SBP was significantly lower in the DTx

intervention group than that in the control group.[12]

Although the HERB-DH1 trial demonstrated the clinical efficacy of DTx, there is still

a lack of cost-effectiveness assessments evaluating the impact of the prescription DTx for

hypertension on healthcare costs along with clinical efficacy. The cost-effectiveness of DTx

for opioid use disorder or that for low back pain were recently evaluated using the RCT

results.[13-15] However, there is no study assessing the cost-effectiveness of prescription DTx for

hypertension using the RCT data. Exploring the appropriate DTx pricing determined by cost-

effectiveness analysis is crucial in countries including Japan, whose DTx costs could be

reimbursed by public health insurance.

Here, we aimed to analyze the cost-effectiveness of using prescription DTx in treating

hypertension using the HERB-DH1 phase III RCT results.

Methods

We developed an economic model to assess the cost and effectiveness of DTx for essential hypertension. The model investigated quality-adjusted life-years (QALYs) and the cost of DTx for hypertension plus guideline-based lifestyle modification consultation treatment as usual (TAU) (DTx+TAU) vs. TAU only with a lifetime horizon and a 1-month cycle length. We constructed the model from the perspective of a public health care payer. We compared the cost-effectiveness of DTx+TAU with TAU alone for the treatment of CAD, stroke, HF, and AFib. We used the parameters of the HERB-DH1 phase III clinical trial[12] as inputs. The HERB-DH1 trial is an open-label RCT of HERB prescription DTx in 390 patients with essential hypertension. At 12 weeks, DTx+TAU intervention group exhibited a significant reduction of SBP compared with the TAU-only control group (-10.6 mmHg in DTx+TAU group vs -6.2 mmHg in the TAU-only control group by a home BP measurement). The present study evaluated outcomes as incremental cost-effectiveness ratio (ICER) per QALY gained. The model inputs were obtained from the HERB-DH1 trial data, published academic papers, publicly available data, and expert assumptions. We conducted the analyses according to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement and the Ethics Guidelines for Medical and Biological Research Involving Human Subjects in Japan. The authors have the right to publish, regardless of the outcome. The Institutional Review Board approved the study protocol at Kanazawa University, Japan.

Model structure and clinical pathway

We developed a monthly cycle Markov model and conducted Monte Carlo simulations to estimate the efficacy of DTx+TAU (**Figure 1**). A Monte Carlo simulation, with 1,000,000 iterations, was performed to reflect the variation in patient characteristics, such as age and treatment effects, mainly derived from those of enrollees for the clinical trial. The model

consisted of patients who received DTx+TAU and those who received TAU only. We modelled

three different health statuses as follows: "stay" (healthy without any acute complications),

"acute complications*"* (suffering any acute complications regarding hypertension), and "death."

Acute complications included CAD, stroke, HF, and AFib. We also considered natural deaths

in the model. Hypertensive patients who avoid natural death can stay in the same acute

complication-free status "stay" or experience acute complications of CAD, stroke, HF, or AFib.

In this model, a patient with one of the acute complications must maintain the "acute

complication" status or die directly from the complication for 12 months, then automatically

recover and switch from the "acute complication" status to the "stay" status with a post-

complication (chronic) tag [return to the "stay" status but had slightly higher mortality rates

than natural deaths in patients after having either of CAD, stroke, and HF]. We did not consider

a patient with more than one complication within 12 months of the latest occurrence of acute

complications.

Time horizon

We set lifetime years (50 years) as the time horizon for our study. We also conducted scenario

analyses to slide the time horizon to 20, 30, and 40 years.

Model population and intervention

The study population was derived from the HERB-DH1 trial. They were grade I or II

hypertensive patients without antihypertensive drug treatment, with a mean age of 52 years,

20% were female, 16% were current smokers, and the proportion of dyslipidemia and diabetes

was 50% and 7%, respectively. The average SBPs was 145 mmHg in the 24-h SBP by

ambulatory BP monitoring and 148 mmHg in the morning home SBP by home BP monitoring.

This model used log-normalized baseline home SBP distribution from HERB-DH1 trial data

(**Table 1**). Additionally, we modelled annual SBP increase in both groups by 0.5 mmHg from

the national survey.[7]

The DTx+TAU group received the prescription DTx, HERB Mobile system, and

lifestyle modifications to manage hypertension recommended by the Japanese Society of

Hypertension (JSH) guidelines.[7] The HERB Mobile system include the HERB Mobile

smartphone app and a web-based management application for healthcare providers. The

smartphone app retrieves each patient's baseline input data, and daily home BP measurements

transfer the data to the cloud server and assess them to plan a personalized lifestyle

modification program to lower their BP. In addition, primary physicians can simultaneously

browse their patients' data such as BP measurements, daily activities, or progress on the

proposed program using a web-based application.[11, 12] The TAU-only group also promoted

lifestyle modifications for hypertension based on the JSH guidelines by their primary

physicians or themselves. We assume that the hypertensive patients in the DTx+TAU group

have an average home SBP reduction of 10.6 mmHg, while those in the TAU-only group had

a 6.2 mmHg reduction from the previous study.[12] In this simulation model, we used DTx+TAU

and TAU-only effect distributions derived from the HERB-DH1 trial data (**Supplemental**

Figure). Since DTx adherence could decrease with time, we set the model such that 25% of

the remaining users in the DTx+TAU group attrited using the DTx every 6 months.

Mortality and complications

We obtained the annual natural death rates from the Japan Vital Statistics for 2022.[16] the annual

mortality and occurrence rates of each complication are summarized in **Table 1**. We set both

acute and post-state (chronic) mortality rates for each complication.[17-21]

The occurrence rates of each complication were adjusted according to the BP categories

(**Supplemental Table**).[17] Additionally, the annual incidence rates of CAD and stroke were

calibrated referring to the previously reported lifetime risks.[22, 23] In addition, the annual

incidence rate of HF was calibrated by a patient's age (hazard ratios [HRs] of 2.5, 5.0, and 10

for the 60s, 70s, and ≥80s).[24] Categories of normal BP, elevated BP, grade I HT, and grade II

HT were defined as home SBPs of <125, 125-134, 135-144, and ≥145 mmHg, respectively.[7]

Since the cycle length of the model was 1 month, we converted the annual rates to the monthly

rates to input the model.

Costs

A list of the cost data is presented in **Table 1**. We performed an economic estimation from

Japan's public healthcare payer perspective, under which only medical costs were considered.

The costs consist of treatment and hospitalization expenses, but not transportation fees or

family care service costs. We set the monthly cost of HERB DTx at ¥10,000 ($86.96 US: $1

US = ¥115 as of January 2022), including the app purchases and subscription fees. The cost of

each complication (CAD, stroke, HF, and AFib) was also derived from previous studies.[25-28]

We set annual cost reduction by 2% according to the Japanese guideline for cost-effectiveness

analyses.[29]

Health-related quality of life and utilities

We derived the utility values of CAD, stroke, HF, and AFib from published studies based on

the European Quality of Life-5 Dimensions Questionnaire (**Table 1**).[28, 30, 31] We calculated the

QALY by multiplying the time duration in a specific health state by the utility value associated

with the state. Both cost and outcome were discounted at a 2% discount rate.[29]

Main analysis

We calculated the ICER between DTx+TAU and TAU-only strategies over the lifetime horizon

using the estimated model parameters and cost and effectiveness assumptions.

Sensitivity and scenario analyses

We tested the impact of the uncertainties around the model parameters on the overall cost-

effectiveness results using one-way deterministic and probabilistic sensitivity analyses. First,

we performed one-way deterministic sensitivity analyses by changing the treatment effect, cost,

and utility parameters over each range between low and high values (**Table 1 and**

Supplemental Table). Then, we conducted probabilistic sensitivity analyses to evaluate the

sensitivity of the results to simultaneous variable changes using a set of 2 million (2,000

iterations × 1,000 individuals) simulated results with specific probability distributions of the

input parameters. We assumed a Weibull distribution for age, log-normal distribution for initial

SBP input, normal distributions for HRs of each complication by BP grades, mortality rates,

and health utilities, beta distributions for clinical event incidence rates, and gamma

distributions for costs. In addition, we drew the probability of the cost-effectiveness

acceptability curve to evaluate the cost-effectiveness probability at a willingness-to-pay

threshold of ¥5 million ($43,478). Additionally, we conducted two scenario analyses as

follows: #1) simulating different time horizons of 20, 30, and 40 years; and #2) setting an

alternative DTx app attrition rate of 10% every 6 months. All model analyses were conducted

using TreeAge Pro HealthCare version 2022 R1.0 (TreeAge Software, LLC, MA, USA).

Results

Main analysis

The model predicted that the DTx+TAU strategy produced 18.778 QALY and was associated with ¥3,924,075 ($34,122) expected costs compared to 18.686 QALY and ¥3,813,358 ($33,160) generated by TAU-only treatment over a lifetime horizon. The introduction of DTx would increase costs by ¥110,717 ($962) and prolong QALY by 0.092. The ICER of DTx+TAU against TAU would be ¥1,199,880 ($10,434)/QALY gained, which were well below the hypothetical threshold value in Japan, or ¥5 million/QALY gained (**Table 2**).

Sensitivity analyses

We conducted one-way deterministic and probabilistic sensitivity analyses. The results of the one-way deterministic sensitivity analyses with the tornado diagram are shown in **Figure 2**. The monthly cost of DTx, which ranged from ¥5,000 ($43.48)/month to ¥20,000 ($173.91)/month, had the largest impact on the ICER value, followed by the DTx attrition and discount rates. According to the one-way threshold analysis for the monthly DTx cost, the DTx+TAU arm became the dominant strategy when the cost was below ¥5,163 ($44.90) per month. Even the highest ICER value observed in this diagram was still below the threshold value, or ¥5 million/QALY gained.

The results of the probabilistic sensitivity analysis are shown with incremental cost-effectiveness scatter plots (**Figure 3**) and a cost-effectiveness acceptability curve (**Figure 4**). According to these figures, the probability of dominance (DTx less costly and more effective) and cost-effectiveness (DTx more costly and more effective, the ICER was less than ¥5 million /QALY gained) were 6.5% and 81.3%, respectively.

Scenario analyses

242   In scenario #1, by changing the simulation duration, the ICERs for DTx+TAU treatment were

243   inversely proportional to the extent of the time horizon (Table 2). In scenario #2, using an

244   alternative DTx attrition rate of 10% every 6 months, ICER was reached in ¥4,330,295

245   ($37,655)/QALY.

Discussion

In this study, we assessed the cost-effectiveness of prescription DTx for essential hypertension, in addition to TAU, compared to the TAU-only strategy. We found that the ICER of the DTx +TAU strategy was ¥1,199,880 ($10,434) /QALY against the TAU-only strategy in the lifetime horizon, which was well below the threshold value, or ¥5 million /QALY. Moreover, the probability of the cost being below the threshold value was 87.8% in the probabilistic sensitivity analysis. This model analysis demonstrated that DTx+TAU is cost-effective for patients with hypertension.

There are several conclusions that can be drawn from this study. First, this is the first study to evaluate the cost-effectiveness of DTx for patients with hypertension using the results of an RCT. Nordyke et al. reported the good cost-effectiveness of DTx for hypertension with person-to-person health coaching from retrospective study data over a 3 year time horizon.[32, 33] Other than hypertension, DTx for opioid use disorder and that for low back pain also revealed cost-effectiveness in a relatively short time horizon (12 weeks to 3 years) without considering mortality rates.[13-15] Although the DTx usage half-time was around 15 months in this model, the benefit of the BP-lowering effect persisted for long life above 3 years, resulting in prevention of the trajectory of CVD from hypertension, left ventricular hypertrophy, atherosclerotic events, and finally to HF and CVD deaths. Therefore, a long-term cost-effectiveness analysis would be valuable when considering the practical effects of DTx for chronic diseases such as hypertension.

The monthly cost of DTx for hypertension had the greatest impact on ICERs in the one-way deterministic sensitivity analysis. Lewkowicz et al. pointed out the similar conclusion by evaluating the cost-effectiveness of DTx for low back pain.[15] At a DTx cost of ¥5,000/month, DTx dominated conventional therapy, or being less costly and more effective option. Even when we set the cost at ¥20,000/month, the ICER was approximately ¥3.5 million/QALY, still

under the threshold value of ¥5 million/QALY (**Figure 2**). Recently, sacubitril/valsartan

(angiotensin receptor-neprilysin inhibitor), a novel antihypertensive drug, was approved for

hypertension management in Japan[34], with a medication cost of ¥6,057 ($52.67) to ¥12,114

($105.34) /month. Thus, the DTx cost we set around ¥10,000/month as the default might be a

reasonable value according to the current simulation model.

The attrition rate of the DTx program is a crucial factor for cost-effectiveness. A

smartphone mHealth app usage rate was attenuating over time, reported approximately 40% of

attrition occurred in 6 months to 1 year.[35] Previous DTx studies for cost-effectiveness analyses

also used similar attrition rates.[15, 32] Thus, it could be reasonable to set the attrition rate of 25%

every 6 months in this model, which half time was around 15 months since the initiation of

DTx. In another scenario, when we changed the rate to 10% (lower than the predefined 25%),

the half time exceeded approximately 40 months, and the ICER was increased to approximately

¥4.3 million/QALY in a lifetime horizon, which was close to the threshold value (**Figure 2**).

Lewkowicz et al. previously reported that lowering the DTx app attrition rate was essential for

cost-effectiveness in a relatively short-term (3 years) horizon.[15] Although the model inputs and

target disease were different, it might be possible that high attrition rates along with DTx actual

usage duration could substantially impact DTx cost-effectiveness. Achieving good cost-

effectiveness in DTx, we might face sensitive handling to balance the appropriate DTx app

usage duration with DTx costs and expected attrition rate.

The degree of the gained ICER in DTx hypertension management surely depends on

the degree of BP reduction by quality of the DTx app algorithm, the impact of BP reduction,

and the cost of cardiovascular events in each country. A significant difference in home BP

reduction (-4.3 mmHg of morning home SBP) was clearly found between the DTx+TAU and

TAU-only groups from the previous phase III clinical trial. It is noteworthy that this TAU-only

group followed the ideal guideline-driven management of hypertension, which used home BP

monitoring.[7] Compared with office BP, home BP is more closely associated with

cardiovascular event risk.[36, 37] In addition, in Asian countries, the benefit of BP lowering is

greater than that of Westerners, especially for stroke.[38] The comparison of cost-effectiveness

studies using different DTx apps in different contigs is also needed in the future.

The strength of this study is that, to our knowledge, this is the first study to evaluate the

cost-effectiveness of DTx for patients with hypertension using the results from an RCT.

Furthermore, we demonstrated that DTx+TAU is cost-effective for patients with hypertension.

This study has some limitations. First, we simulated middle-aged, digital-friendly grade I or II

hypertensive patients without taking antihypertensive medication from the previous RCT

results. Thus, caution should be taken when applying our results to a broader population.

Second, we modelled the DTx effect as permanent, although the effect estimates were derived

from the 6-months duration of the HERB-DH1 trial results. Although we set the BP reduction

effects even for the TAU-only strategy, this could lower the mortality and complication

occurrence rates in the DTx+TAU strategy. Third, we did not estimate additive effects of

having multiple comorbidities in this model, which could impact lifetime ICER. Fourth, we

could not strictly assess the DTx cost-effectiveness in addition to antihypertensive medications

since the model patients derived from previous trials were all antihypertensive drug-naïve.

Finally, we did not consider re-using DTx after finishing the initial DTx usage according to the

attrition rate, which could account for additional costs for the DTx strategy.

In conclusion, DTx+TAU demonstrated good cost-effectiveness in hypertensive

patients compared to the TAU-only strategy. DTx cost and its attrition rate largely influenced

cost-effectiveness, and we need to explore the balance among the DTx application cost, app

attrition rate, and effectiveness for target hypertensive patients in clinical practice. DTx is

generally reimbursed by Japan's national universal health insurance system. Thus, it is

becoming increasingly essential to evaluate the cost-effectiveness of DTx, as in this study, to

consider the appropriate value-based reimbursement pricing.

Acknowledgments

We would like to express our gratitude to all participants regarding this study.

Source of funding

The HERB-DH1 RCT, the data of which were used in this study, was sponsored by CureApp,

Inc. (Tokyo, Japan). In addition, CureApp Inc. has patents and distribution rights for the HERB

mobile prescription DTx system.

Disclosures

Akihiro Nomura, Kazuomi Kario, and Ataru Igarashi received consulting fees from CureApp

Inc. Akihiro Nomura was co-founder of the CureApp Institute. Tomoyuki Tanigawa is the chief

medical officer of CureApp, Inc.

References

1.   World Health Organization. Hypertension. Aug 25, 2021;(Last accessed: Jan 29,
2022).

2.   G. B. D. Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries
and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
2019. *Lancet*. 2020;396:1223-1249.

3.   Ministry of Health Labour and Welfare. Japan National Health and Nutrition Survey
2017. (Last accessed: Dec 1,2021).

4.   Fujiyoshi A, Ohkubo T, Miura K, Murakami Y, Nagasawa SY, Okamura T, Ueshima
H and Observational Cohorts in Japan Research G. Blood pressure categories and long-term
risk of cardiovascular disease according to age group in Japanese men and women. *Hypertens*
Res. 2012;35:947-53.

5.   Matsumoto K, Hanaoka S, Wu Y and Hasegawa T. Comprehensive Cost of Illness of
Three Major Diseases in Japan. *J Stroke Cerebrovasc Dis*. 2017;26:1934-1940.

6.   Special Committee on Planning of Next National Health Promotion Campaign Health
Sciences Council. Information material on the promotion of Health Japan 21 (Second edition)
(July 2012). (Last accessed: Jul 16, 2019).

7.   Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide
S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N,
Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H,
Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura
T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K,
Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H and Hirawa N. The Japanese
Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).
Hypertens Res. 2019;42:1235-1481.

8.   Wang J, Qiu B, Du JL, Deng SB, Liu YJ and She Q. The effects of a low-salt diet on
the efficacy of different antihypertensive drug regimens. *J Clin Pharmacol*. 2015;55:1362-8.

9.   Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA,
Lewin AJ, Mennella RF, Kirkegaard LW, Hamilton JH, Weinberger MH and Weder AB.
Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-
converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives.
Hypertension. 1998;31:1088-96.

10.   Nishigaki N, Shimasaki Y, Yoshida T and Hasebe N. Physician and patient

perspectives on hypertension management and factors associated with lifestyle modifications

in Japan: results from an online survey. *Hypertens Res*. 2020;43:450-462.

11.   Kario K, Nomura A, Harada N, Tanigawa T, So R, Nakagawa K, Suzuki S, Okura A,

Hida E and Satake K. A multicenter clinical trial to assess the efficacy of the digital

therapeutics for essential hypertension: Rationale and design of the HERB-DH1 trial. *J Clin*

Hypertens (Greenwich). 2020;22:1713-1722.

12.   Kario K, Nomura A, Harada N, Okura A, Nakagawa K, Tanigawa T and Hida E.

Efficacy of a digital therapeutics system in the management of essential hypertension: the

HERB-DH1 pivotal trial. *Eur Heart J*. 2021;42:4111-4122.

13.   Wang W, Gellings Lowe N, Jalali A and Murphy SM. Economic modeling of reSET-

O, a prescription digital therapeutic for patients with opioid use disorder. *J Med Econ*.

2021;24:61-68.

14.   Velez FF and Malone DC. Cost-Effectiveness Analysis of a Prescription Digital

Therapeutic for the Treatment of Opioid Use Disorder. *J Mark Access Health Policy*.

2021;9:1966187.

15.   Lewkowicz D, Wohlbrandt AM and Bottinger E. Digital Therapeutic Care Apps With

Decision-Support Interventions for People With Low Back Pain in Germany: Cost-

Effectiveness Analysis. *JMIR Mhealth Uhealth*. 2022;10:e35042.

16.   Ministry of Internal Affiairs and Communications Statistics Bureau. Japan Statistical

Yearbook 2022 (Chapter 2-22 Life Table). (Last accessed: Feb 11, 2022).

17.   Kaneko H, Yano Y, Itoh H, Morita K, Kiriyama H, Kamon T, Fujiu K, Michihata N,

Jo T, Takeda N, Morita H, Node K, Carey RM, Lima JAC, Oparil S, Yasunaga H and

Komuro I. Association of Blood Pressure Classification Using the 2017 American College of

Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart

Failure and Atrial Fibrillation. *Circulation*. 2021;143:2244-2253.

18.   Komiyama K, Nakamura M, Tanabe K, Niikura H, Fujimoto H, Oikawa K, Daida H,

Yamamoto T, Nagao K, Takayama M and Tokyo CCUNSC. In-hospital mortality analysis of

Japanese patients with acute coronary syndrome using the Tokyo CCU Network database:

Applicability of the GRACE risk score. *J Cardiol*. 2018;71:251-258.

19.   Goto S, Ikeda Y, Shimada K, Uchiyama S, Origasa H, Kobayashi H and Investigators

JT. One-year cardiovascular event rates in Japanese outpatients with myocardial infarction,

stroke, and atrial fibrillation. -Results From the Japan Thrombosis Registry for Atrial

Fibrillation, Coronary, or Cerebrovascular Events (J-TRACE). *Circ J*. 2011;75:2598-604.

20.   Shiraishi Y, Kohsaka S, Sato N, Takano T, Kitai T, Yoshikawa T and Matsue Y. 9-

Year Trend in the Management of Acute Heart Failure in Japan: A Report From the National

Consortium of Acute Heart Failure Registries. *J Am Heart Assoc*. 2018;7:e008687.

21.   Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T,

Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H and Investigators C-.

Characterization of heart failure patients with mid-range left ventricular ejection fraction-a

report from the CHART-2 Study. *Eur J Heart Fail*. 2017;19:1258-1269.

22.   Turin TC, Kokubo Y, Murakami Y, Higashiyama A, Rumana N, Watanabe M and

Okamura T. Lifetime risk of acute myocardial infarction in Japan. *Circ Cardiovasc Qual*

Outcomes. 2010;3:701-3.

23.   Turin TC, Okamura T, Afzal AR, Rumana N, Watanabe M, Higashiyama A, Nakao

Y, Nakai M, Takegami M, Nishimura K, Kokubo Y, Okayama A and Miyamoto Y.

Hypertension and lifetime risk of stroke. *J Hypertens*. 2016;34:116-22.

24.   Fujimoto W, Toh R, Takegami M, Hayashi T, Kuroda K, Hatani Y, Yamashita S,

Imanishi J, Iwasaki M, Inoue T, Okamoto H, Okuda M, Konishi A, Shinohara M, Murata S,

Ogata S, Nishimura K and Hirata KI. Estimating Incidence of Acute Heart Failure

Syndromes in Japan- An Analysis From the KUNIUMI Registry. *Circ J*. 2021;85:1860-1868.

25.   Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, Phatak H, Liu LZ,

Tang AC, Feng Wang P and Okumura K. Cost-effectiveness Analysis of Apixaban against

Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. *Clin*

Ther. 2015;37:2837-51.

26.   Mizuno A, Iguchi H, Sawada Y, Hurley M, Nomura H, Hayashi K, Tokuda Y,

Watanabe S and Yoshikawa A. The impact of carperitide usage on the cost of hospitalization

and outcome in patients with acute heart failure: High value care vs. low value care campaign

in Japan. *Int J Cardiol*. 2017;241:243-248.

27.   Kamae I, Kitamura A, Sakurai M, Yamamoto M, Inoue S, Shibahara H and

Kobayashi M. Economic burden of arterial fibrillation in Japan (abstract). *Value Health*.

2018;21:S70.

28.   Kodera S, Morita H, Kiyosue A, Ando J and Komuro I. Cost-Effectiveness of

Percutaneous Coronary Intervention Compared With Medical Therapy for Ischemic Heart

Disease in Japan. *Circ J*. 2019;83:1498-1505.

29.   Shiroiwa T, Fukuda T, Ikeda S, Takura T and Moriwaki K. Development of an

Official Guideline for the Economic Evaluation of Drugs/Medical Devices in Japan. *Value*

Health. 2017;20:372-378.

30.   Hattori N, Hirayama T and Katayama Y. Medical care for chronic-phase stroke in
Japan. *Neurol Med Chir (Tokyo)*. 2012;52:175-80.
31.   Clarke P, Gray A and Holman R. Estimating utility values for health states of type 2
diabetic patients using the EQ-5D (UKPDS 62). *Med Decis Making*. 2002;22:340-9.
32.   Nordyke RJ, Appelbaum K and Berman MA. Estimating the Impact of Novel Digital
Therapeutics in Type 2 Diabetes and Hypertension: Health Economic Analysis. *J Med*
Internet Res. 2019;21:e15814.
33.   Guthrie NL, Berman MA, Edwards KL, Appelbaum KJ, Dey S, Carpenter J,
Eisenberg DM and Katz DL. Achieving Rapid Blood Pressure Control With Digital
Therapeutics: Retrospective Cohort and Machine Learning Study. *JMIR Cardio*.
2019;3:e13030.
34.   Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H and Zhang J. Efficacy of
sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a
randomized, double-blind, multicenter study. *Hypertens Res*. 2022.
35.   Meyerowitz-Katz G, Ravi S, Arnolda L, Feng X, Maberly G and Astell-Burt T. Rates
of Attrition and Dropout in App-Based Interventions for Chronic Disease: Systematic Review
and Meta-Analysis. *J Med Internet Res*. 2020;22:e20283.
36.   Kario K, Shimbo D, Hoshide S, Wang JG, Asayama K, Ohkubo T, Imai Y, McManus
RJ, Kollias A, Niiranen TJ, Parati G, Williams B, Weber MA, Vongpatanasin W, Muntner P
and Stergiou GS. Emergence of Home Blood Pressure-Guided Management of Hypertension
Based on Global Evidence. *Hypertension*. 2019:HYPERTENSIONAHA11912630.
37.   Kario K. State-of-the-Art review: Home blood pressure monitoring: current status and
new developments. *Am J Hypertens*. 2021.
38.   Kario K, Park S, Chia YC, Sukonthasarn A, Turana Y, Shin J, Chen CH,
Buranakitjaroen P, Divinagracia R, Nailes J, Hoshide S, Siddique S, Sison J, Soenarta AA,
Sogunuru GP, Tay JC, Teo BW, Zhang YQ, Van Minh H, Tomitani N, Kabutoya T, Verma
N, Wang TD and Wang JG. 2020 Consensus summary on the management of hypertension in
Asia from the HOPE Asia Network. *J Clin Hypertens (Greenwich)*. 2020;22:351-362.
463

Figure legends

Figure 1. Structure of the simulation model.

A) Decision tree. B) Structure of Markov model. C) Structure of Stay (no acute

complications) module. D) Structure of acute complications module.

Figure 2. One-way sensitivity analysis results.

Figure 3. Cost-effectiveness plot.

Figure 4. Cost-effectiveness acceptability curve in DTx+TAU and TAU-only group.

Tables

Table 1. Model inputs.

Data	Input	Low*	High*	Source
Age	52.3 years	-	-	Kario, 2021.
Baseline SBP	148 mmHg	-	-	Kario, 2021.
Annual BP increase	0.5 mmHg	0.39	0.65	Umemura, 2019
Annual mortality rates by complications				
Coronary artery disease				
First 1 month after event onset	5.0% / month	0	5.0	Komiyama, 2018.
> 1 month (post-CAD)	0.98%	0.93	1.74	Goto, 2011.
Stroke				
First 1 month after event onset	12.9% / month	9.7	16.1	Takashima, 2017.
> 1 month (post-Stroke)	1.29%	-	-	Goto, 2011.
Heart failure				
First 12 months after event onset	11.5%	10.1	13.0	Shiraishi, 2018.
>13 months (post-HF)	2.5%	-	-	Tsuji, 2017.
Atrial fibrillation				
First 12 months after event onset	1.83%	1.28	2.56	Goto, 2011.
>13 months (post-AFib)	Same as the natural mortality rate			-
Annual incidence rates of each complication among hypertension patients				
Coronary artery disease	0.460%	0.345	0.575	Kaneko, 2021. Turin, 2010.
Stroke	1.592%	1.194	1.990	Kaneko, 2021. Turin, 2016.
Heart failure	0.889%	-	-	Kaneko, 2021. Fujimoto 2021.
Atrial fibrillation	0.232%	-	-	Kaneko, 2021.
Annual costs				
DTx for hypertension	¥120,000 ($1,043)	60,000	240,000	Assumption
Acute phase (First 12 months after event onset)				
Coronary artery disease	¥2,156,290 ($18,750)	1,617,218	2,695,362	Kamae, 2015.
Stroke	¥1,440,107 ($12,523)	1,080,080	1,800,134	Kamae, 2015.
Heart failure	¥770,428 ($6,699)	577,821	963,035	Mizuno, 2017.
Atrial fibrillation	¥120,000 ($1,043)	90,000	150,000	Kamae, 2018.
Post-complication phase (>12 months)				
Coronary artery disease	¥495,600 ($4,310)	459,996	570,000	Kodera, 2019
Stroke	¥318,387 ($2,769)	262,992	372,996	Kodera, 2019
Heart failure	¥770,428 ($6,699)	577,821	963,035	Mizuno, 2017.
Atrial fibrillation	¥120,000 ($1,043)	90,000	150,000	Kamae, 2018.
Health utilities				
Normal	0.950	0.760	1.000	-
Coronary artery disease (increment)	-0.180	-0.135	-0.225	Kodera, 2019.
Stroke (increment)	-0.157	-0.117	-0.196	Hattori, 2012.
Heart failure (increment)	-0.101	-0.076	-0.126	Clarke 2002.
Atrial fibrillation (increment)	-0.000	-	-	Assumption
Death (increment)	-0.950	-	-	-
Discount rates	2%	0	4	Shiroiwa, 2017.

477 * Range for sensitivity analysis.

478   Abbreviations: AF, atrial fibrillation; BP, blood pressure; CAD, coronary artery disease; CI,

479   confidence interval; HF, heart failure; SBP, systolic blood pressure.

480 **Table 2. Cost-effectiveness of DTx for hypertension.**

Outcome	DTx+TAU	TAU-only	Changes
Lifetime horizon			
Costs	¥3,924,075 ($34,122)	¥3,813,358 ($33,160)	¥110,717 ($962)
QALYs	18.778	18.686	0.092
ICER		**¥1,199,880 ($10,434)/QALY**	
40-year time horizon			
Costs	¥3,705,428	¥3,591,385	¥114,043
QALYs	18.483	18.395	0.089
ICER		**¥1,284,159 ($11,167)/QALY**	
30-year time horizon			
Costs	¥2,996,162	¥2,869,894	¥126,268
QALYs	17.195	17.124	0.071
ICER		**¥1,788,344 ($15,551)/QALY**	
20-year time horizon			
Costs	¥1,820,066	¥1,664,483	¥155,583
QALYs	13.939	13.903	0.037
ICER		**¥4,235,677 ($36,832)/QALY**	

483 Abbreviations: DTx, digital therapeutics; ICER, incremental cost-effectiveness ratio; QALY,

484 quality-adjusted life year; TAU, treatment as usual

Figures

Figure 1.

498   **Figure 2.**

ICER

505 **Figure 3.**

511   **Figure 4.**

513   1.0

514   0.9

515   0.8

517   0.7

0.6

0.5

0.4

0.3

0.2

0.1

Probability of chosen as "most cost-effective" option

Threshold value for 1 QALY gained (JPY¥)

DTx + TAU
TAU-only